Shay Capital LLC Acquires New Shares in Kezar Life Sciences, Inc. (NASDAQ:KZR)

Shay Capital LLC bought a new stake in Kezar Life Sciences, Inc. (NASDAQ:KZR) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 59,158 shares of the company’s stock, valued at approximately $398,000. Shay Capital LLC owned about 0.81% of Kezar Life Sciences as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. grew its position in Kezar Life Sciences by 613.8% in the fourth quarter. JPMorgan Chase & Co. now owns 11,884 shares of the company’s stock valued at $80,000 after acquiring an additional 10,219 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in Kezar Life Sciences in the fourth quarter valued at about $217,000. BML Capital Management LLC bought a new position in Kezar Life Sciences in the fourth quarter valued at about $327,000. Finally, Peapod Lane Capital LLC bought a new position in Kezar Life Sciences in the fourth quarter valued at about $833,000. Institutional investors own 67.90% of the company’s stock.

Analyst Ratings Changes

Separately, William Blair reiterated an “outperform” rating on shares of Kezar Life Sciences in a research report on Friday, February 28th.

Kezar Life Sciences Stock Performance

Kezar Life Sciences stock opened at $4.07 on Friday. The stock has a market cap of $29.74 million, a PE ratio of -0.31 and a beta of 0.61. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.05. The business’s 50-day moving average price is $4.64 and its two-hundred day moving average price is $5.95. Kezar Life Sciences, Inc. has a 12-month low of $3.62 and a 12-month high of $9.18.

Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($2.27) earnings per share for the quarter, topping the consensus estimate of ($2.56) by $0.29. As a group, analysts expect that Kezar Life Sciences, Inc. will post -4.39 earnings per share for the current fiscal year.

Kezar Life Sciences Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.